



Europass Curriculum Vitae



Personal information

First name(s) / Surname(s) **Massimiliano Salati**
 Address(es) 26, via F. Confalonieri, 41125, Modena, Italy
 Telephone(s) Mobile: +39-3394624778
 E-mail maxsalati@live.it; massisalati@gmail.com
 Nationality Italian
 Date of birth 14/02/1988
 Gender Male

Desired employment / Occupational field

Medical Oncologist, University Hospital of Modena

Dates June 2022 to Present

Translational research fellowship

Dates January 2018 to January 2019

Occupation or position held Research fellow within the Gastrointestinal Cancer Biology and Genomics Team at the Institute for Cancer Research and the GI Unit at the Royal Marsden Hospital (London, UK),

Main activities and responsibilities Laboratory activities (DNA and RNA extractions, PCR, cell culture) and clinical activity (observership in outpatients clinic participating in and carrying out activities concerning II and III clinical trials).

Medical Oncology Residency

Dates December 2014 to December 2019

Occupation or position held Resident in Medical Oncology at the Modena Cancer Centre, University of Modena and Reggio Emilia, Modena, Italy.

Main activities and responsibilities Participate in and carry out activities regarding inpatients and outpatients, grand rounds, and multidisciplinary meetings (Prof. Cascinu).

Internship in Medical Oncology

Dates May 2013 to March 2014

Occupation or position held Medical Student

Main activities and responsibilities Participate in and carry out activities regarding inpatients and outpatients, grand rounds, and multidisciplinary meetings (Prof. Federico, Prof. Stefano Luminari).

Education and training Clinical research fellowship

Dates March 2014 to June 2014

Title of qualification awarded Research fellow in the clinical trial unit with focus on early drug development

Principal subjects/occupational skills covered Participate in and carry out activities concerning phase I, II and III clinical trials. Attend to multicenter phoneconferences, site and initiation visits. Learn how to set up a clinical study, how to follow patients within a study, which is the logistics of early clinical trials and the data collection.

Name and type of organisation providing education and training Oncology Institute of Southern Switzerland in Bellinzona (Prof.ssa Sessa, Prof. Cavalli, Dott. Stathis)

Personal skills and competences

Mother tongue(s) Italian

Other language(s) English, French

IELTS ACADEMIC TEST

Understanding		Speaking and Writing		Overall Band Score
Listening	Reading	Speaking	Writing	
7.5	8.5	6.5	6.5	7.5 (C1*)

Scientific publications

- 1- **Salati M**, Cesaretti M, Macchia M, Mistiri ME, Federico M. Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin. *Mediterr J Hematol Infect Dis*. 2014 Jul 1;6(1):e2014048. doi: 10.4084/MJHID.2014.048. eCollection 2014. Review.
- 2- Biasoli I, Cesaretti M, Bellei M, Maiorana A, Bonacorsi G, Quaresima M, **Salati M**, Federico M, Luminari S. Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. *Hematol Oncol*. 2014 Apr 29;doi: 10.1002/hon.2144. [Epub ahead of print].
- 3- Federico M, **Salati M**. Current approaches in the treatment of Hodgkin Lymphoma. *Hematology Education: the education program for the annual congress of the European Hematology Association (EHA)*.2014; 8(1).
- 4- Federico M, Pesce EA, Merli F, Luminari S, Chauvie S, Pellegrini C, Marcheselli L, Capodanno I, Ilariucci F, **Salati M**, Argnani L, Zinzani PL. A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma. A preliminary report. Abstract #125756 accepted in the oral abstract session at the 2014 ASCO Annual Meeting.
- 5- Luminari S, Dondi A, Marcheselli L, Rossi G, Boccomini C, Chiarenza A, Rigacci L, Merli F, Bertoldero G, Levis A, Ferreri AJ, Vallisa D, Cox MC, Balzarotti M, **Salati M**, Federico M. Updated results of the FOLL05 phase III trial from the fondazione italiana linfomi comparing R-CVP, R-CHOP and R-FM in patients with advanced follicular lymphoma. Abstract #131262 accepted in the poster presentation session at the 2014 ASCO Annual Meeting.
- 6- **Salati M**, Cesaretti M, Luminari S, Federico M. Management of refractory/relapsed diffuse large B-cell lymphoma (DLBCL): the gap between guidelines and real world. Abstract accepted as poster presentation at the 2014 General Annual Meeting of the Belgian Hematological Society (BHS).
- 7- Federico M, Macchia M, **Salati M**, Bellei M. To BEACOPP or not to BEACOPP: That is the question. Abstract invited lecture at the 2014 General Annual Meeting of the Belgian Hematological Society (BHS).
- 8- **Salati M**, Bertoni F, Zucca E and Stathis A. Targeting cancer epigenetics: the BET inhibitors. *Schweizer Krebsbulletin* Nr. 2/2014.
- 9- **Salati M**, Stathis A. Sonidegib phosphate. Smoothened (SMO) receptor antagonist, Oncolytic. *Drugs Fut* 2014, 39(10): 677.
- 10- Federico M, **Salati M**, Badiali S. What is next in the treatment of Hodgkin lymphoma. 2nd Saudi Lymphoma/Myeloma Meeting; 13 September 2014, University of Damman. Abstract.
- 11- Zinzani PL, Luminari S, Merli F, Pesce EA, Chauvie S, Pellegrini C, Marcheselli L, Capodanno I, Ilariucci F, **Salati M**, Argnani L, Federico M. Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma: a Pilot Phase II Study. Program: Oral and Poster Abstracts #3088 at the 2014 56th ASH Annual Meeting.
- 12- El Mistiri M, **Salati M**, Marcheselli L, Attia A, Habil S, Alhomri F, Spika D, Allemanni C, Federico M. Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry. *Ann Epidemiol*. 2015 Mar 21. pii: S1047-2797(15)00122-2. doi:10.1016/j.annepidem.2015.03.012.
- 13- Luminari S, Ceriani L, Dührsen U. FDG-PET (CT)-adapted trials in non-Hodgkin lymphoma. *Clinical and Translational Imaging* (2015-08-01) 3: 295-307, August 01, 2015. **Dr. Massimiliano Salati** was acknowledged for his support in manuscript preparation and review.
- 14- Federico M, Luminari S, Pellegrini C, Merli F, Pesce EA, Chauvie S, Gandolfi L, Capodanno I, **Salati M**, Argnani L, Zinzani PL. Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. *Haematologica*. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24.
- 15- Stathis A, Griguolo G, **Salati M**, Rossi L, Zucca E, Sessa C. Primi quattro casi al mondo di carcinoma NUT della linea mediana, trattati con OTX015, un inibitore dei bromodomini (BRD) 2, 3, 4. Quinta Giornata della Ricerca della Svizzera Italiana, Febbraio 2015, Lugano.
- 16- **Salati M**, Tarantino V, Maiorana A, Bettelli S, Luminari S. Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. *Hematol Oncol*. 2016 Jun 15. doi: 10.1002/hon.2315. [Epub ahead of print].
- 17- Manenti A, Roncati L, **Salati M**, Simonini E, Zizzo M, Farinetti A. Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system. *Journal of Gastrointestinal Oncology*. Publish Ahead of Print.

- 18- Manenti A, Roncati L, **Salati M**, Simonini E, Zizzo M and Farinetti A. Restaging rectal cancer after neoadjuvant chemo radiotherapy: For a down-staging classification. 9th Euro Global Gastroenterology Conference October 24-25, 2016 Valencia, Spain. J Gastrointest Dig Syst.
- 19- Manenti A, **Salati M**, Farinetti A, Zizzo M, Simonini E. Rectal tumor recurrence: What more may we learn? Arch Clin Exp Surg 2016.
- 20- Andrikou K, Peterle C, Pipitone S, **Salati M**, Cascinu S. Emerging antibodies for the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2017 Mar;22(1):39-51.
- 21- **Salati M**, Orsi G, Reggiani Bonetti L, Di Benedetto F, Longo G, Cascinu S. Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity. World J Gastrointest Oncol. 2017 Mar 15;9(3):135-141.
- 22- Andrikou K, **Salati M**, Fontana A, Spallanzani A, Pipitone S, Gelsomino F, Barbolini M & Cascinu S. Advanced gastric cancer: is there an optimal chemotherapy regimen? Expert Review of Quality of Life in Cancer Care Vol. 2 , Iss. 2,2017.
- 23- **Salati M**, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open July 19, 2 (3) e000206; DOI: 10.1136/esmoopen-2017-000206.
- 24- **Salati M**, Pifferi M, Baldessari C, Bertolini F, Tomasello C, Cascinu S, Barbieri F. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 2018 Jan 1;29(1):283-284. doi: 10.1093/annonc/mdx640.
- 25- **Salati M**, Baldessari C, Cerbelli B, Botticelli A. Nivolumab in pretreated non-small cell lung cancer: continuing the immunolotion. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14.
- 26- **Salati M**, Cascinu S. Anti-EGFR therapy in oesophagogastric cancer: precise but not enough. Ann Oncol. 2018 Aug 1;29(8):1884-1885. doi: 10.1093/annonc/mdy199.
- 27- Botticelli A, Cerbelli B, Lionetto L, Zizzari I, **Salati M**, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.
- 28- **Salati M**, Baldessari C, Calabrese F, Rossi G, Pettorelli E, Grizzi G, Dominici M, Barbieri F. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. Case Rep Oncol. 2018 Sep 7;11(3):615-621. doi: 10.1159/000492666. eCollection 2018 Sep-Dec.
- 29- **Salati M**, Valeri N, Spallanzani A, Braconi C, Cascinu S. Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol. 2018 Nov 10. pii: S0748-7983(18)31997-8. doi: 10.1016/j.ejso.2018.11.006.
- 30- **Salati M**, Braconi C. Noncoding RNA in Cholangiocarcinoma. Semin Liver Dis. 2019 Feb;39(1):13-25. doi: 10.1055/s-0038-1676097. Epub 2018 Dec 7.
- 31- Adeva J, Sangro B, **Salati M**, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Medical treatment for cholangiocarcinoma. Liver Int. 2019 May;39 Suppl 1:123-142. doi: 10.1111/liv.14100. Review.
- 32- Botticelli A, **Salati M**, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. J Transl Med. 2019 Mar 27;17(1):99. doi: 10.1186/s12967-019-1847-x.

Editorial Board Membership

- World Journal of Gastrointestinal Oncology (Number ID: 03728442, from 01-01-2018 to 31-12-2021)

Reviewer's activity

- Journal of Oncology
- PlosOne
- Future Oncology

Awards	<ul style="list-style-type: none"> - Study Award for the attainment of medical degree from Fondazione Cassa di Risparmio Carpi, Modena, Italy (13 May 2014) - Case presenter and participant in the ESMO Preceptorship on "Gastric Cancer: Multidisciplinary management, standards of care, therapeutic targets and future perspectives" (6-7 October 2017, Valencia, Spain, co-chairs: A. Cervantes; F. Lordick).
Presentations at Congress	<ul style="list-style-type: none"> - M Salati F Caputo A Spallanzani M Rimini F Gelsomino K Andrikou S Cascinu. 770P A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). Annals of Oncology, Volume 29, Issue suppl_8, October 2018 - Salati M, Caputo F, Marcheselli L, Rimini R, Spallanzani A, Gelsomino F, Andrikou K, Zironi S, Di Emidio K, Clo' V, Luppi G, Cascinu S. Second-line chemotherapy in advanced biliary tract cancer: Who may benefit?. Journal of Clinical Oncology 37, no. 4_suppl (February 1 2019) 381-381.
Oral Presentations	<ul style="list-style-type: none"> - Gastro Journal Club. Roma 8-9 Novembre 2018. - Tumori del tratto gastrointestinale: tra scienza e pratica. VIII Workshop nazionale. Bergamo, 23-24 maggio 2019 - Stage on SITE: Ottimizzazione del trattamento del carcinoma gastrico. 18-19 Giugno 2019
Conferences Attended	<ul style="list-style-type: none"> - 3rd Pancreatic Cancer Forum. Milano, November 6th-7th, 2015. - Multidisciplinary experiential training on gastric oncology (MANTEGNA PROJECT). Padova, Palazzo Salute, 10-11 Marzo 2016. - Tumori Neuroendocrini: POST-ENETS 2016. Modena, 1 Aprile 2016. - NEN Preceptorship: La pratica clinica nelle neoplasie neuroendocrine. Milano, Istituto Europeo di Oncologia, 21-22 Aprile 2016. - Apatinib "ANGEL" Study Investigator Meeting in Rome (Monday 20 March 2017)
Scientific Society Membership	<ul style="list-style-type: none"> - European Society of Medical Oncology (ESMO) Junior Membership (From December 2015). - European Network for the study of Cholangiocarcinoma (ENS-CCA; From June 2018) - American Society for Medical Oncology (ASCO). - Gruppo Italiano Colangiocarcinoma (GICO).
ORCID	0000-0002-5579-7454

*I give authorization to read and handle my personal data in accordance with
Legislative Decree no. 196/2003.*